Abstract
Cyclosporine (CsA) is a substrate of cytochrome P450 (CYP) 3A5 and has a narrow therapeutic range with large inter-individual variability. CYP3A5*3 polymorphism is reported to be functional and may contribute to the inter-individual variability. The objective of this meta-analysis was to accurately estimate the effect of CYP3A5*3 allele on CsA dose-adjusted blood concentration. A computerized literature search was conducted in PubMed. A total of 12 and 6 studies meeting the inclusion criteria were, respectively, included in meta-analysis about dose-adjusted trough concentration (C0/D) and dose-adjusted peak concentration (C2/D). The combined weighted mean difference (WMD) between CYP3A5 expressers (*1/*3 + *1/*1) and non-expressers (*3/*3) was significant in C2/D (WMD=−12.73 (ng ml–1)/(mg kg–1), 95% confidence interval (CI) −25.23 to −0.22, P=0.046), whereas it was marginally significant in C0/D (WMD=−3.75 (ng ml–1)/(mg kg–1), 95% CI −7.58 to 0.07, P=0.054). Exclusion of an outlier study greatly increased the association of CYP3A5 polymorphism with C0/D to be significant (WMD=−4.92 (ng ml–1)/(mg kg–1), 95% CI: −8.27 to −1.58, P=0.011). This meta-analysis showed that CYP3A5*3 polymorphism is associated with CsA dose-adjusted concentration in renal transplant recipients. Patients carrying the CYP3A5*3/*3 genotype will require a lower dose of CsA to reach target levels compared with the CYP3A5*1/*1 or *1/*3 carriers.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 6 print issues and online access
$259.00 per year
only $43.17 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Lindholm A, Kahan BD . Influence of cyclosporine pharmacokinetics, trough concentrations, and AUC monitoring on outcome after kidney transplantation. Clin Pharmacol Ther 1993; 54: 205–218.
Kahan BD, Keown P, Levy GA, Johnston A . Therapeutic drug monitoring of immunosuppressant drugs in clinical practice. Clin Ther 2002; 24: 330–350.
Lindholm A . Factors influencing the pharmacokinetics of cyclosporine in man. Ther Drug Monit 1991; 13: 465–477.
Ducharme MP, Warbasse LH, Edwards DJ . Disposition of intravenous and oral cyclosporine after administration with grapefruit juice. Clin Pharmacol Ther 1995; 57: 485–491.
Kronbach T, Fischer V, Meyer UA . Cyclosporine metabolism in human liver: identification of a cytochrome P-450III gene family as the major cyclosporine-metabolizing enzyme explains interactions of cyclosporine with other drugs. Clin Pharmacol Ther 1998; 43: 630–635.
Paine MF, Hart HL, Ludington SS, Haining RL, Rettie AE, Zeldin DC . The human intestinal cytochrome P450 ‘pie’. Drug Metab Dispos 2006; 34: 880–886.
Lamba JK, Lin YS, Schuetz EG, Thummel KE . Genetic contribution to variable human CYP3A-mediated metabolism. Adv Drug Deliv Rev 2002; 54: 1271–1294.
Lamba JK, Lin YS, Thummel K, Daly A, Watkins PB, Strom S et al. Common allelic variants of cytochrome P4503A4 and their prevalence in different populations. Pharmacogenetics 2002; 12: 121–132.
Kuehl P, Zhang J, Lin Y, Lamba J, Assem M, Schuetz J et al. Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat Genet 2001; 27: 383–391.
Anglicheau D, Legendre C, Beaune P, Thervet E . Cytochrome P450 3A polymorphisms and immunosuppressive drugs: an update. Pharmacogenomics 2007; 8: 835–849.
Hu YF, Qiu W, Liu ZQ, Zhu LJ, Liu ZQ, Tu JH et al. Effects of genetic polymorphisms of CYP3A4, CYP3A5 and MDR1 on cyclosporine pharmacokinetics after renal transplantation. Clin Exp Pharmacol Physiol 2006; 33: 1093–1098.
Qiu XY, Jiao Z, Zhang M, Zhong LJ, Liang HQ, Ma CL et al. Association of MDR1, CYP3A4*18B, and CYP3A5*3 polymorphisms with cyclosporine pharmacokinetics in Chinese renal transplant recipients. Eur J Clin Pharmacol 2008; 64: 1069–1084.
Wang Y, Wang C, Li J, Wang X, Zhu G, Chen X et al. Effect of genetic polymorphisms of CYP3A5 and MDR1 on cyclosporine concentration during the early stage after renal transplantation in Chinese patients co-treated with diltiazem. Eur J Clin Pharmacol 2009; 65: 239–247.
Hesselink DA, van Schaik RH, van der Heiden IP, van der Werf M, Gregoor PJ, Lindemans J et al. Genetic polymorphisms of the CYP3A4, CYP3A5, and MDR-1 genes and pharmacokinetics of the calcineurin inhibitors cyclosporine and tacrolimus. Clin Pharmacol Ther 2003; 74: 245–254.
Wang J . CYP3A polymorphisms and immunosuppressive drugs in solid-organ transplantation. Expert Rev Mol Diagn 2009; 9: 383–390.
Kreutz R, Zürcher H, Kain S, Martus P, Offermann G, Beige J . The effect of variable CYP3A5 expression on cyclosporine dosing, blood pressure and long-term graft survival in renal transplant patients. Pharmacogenetics 2004; 14: 665–671.
Hozo SP, Djulbegovic B, Hozo I . Estimating the mean and variance from the median, range, and the size of a sample. BMC Med Res Methodol 2005; 5: 13.
Jiang ZP, Wang YR, Xu P, Liu RR, Zhao XL, Chen FP . Meta-analysis of the effect of MDR1 C3435T polymorphism on cyclosporine pharmacokinetics. Basic Clin Pharmacol Toxicol 2008; 103: 433–444.
Huffcutt AI, Arthur Jr W . Development of a new outlier statistic for meta-analytic data. J Appl Psychol 1995; 80: 327–334.
Anglicheau D, Thervet E, Etienne I, Hurault De Ligny B, Le Meur Y, Touchard G et al. CYP3A5 and MDR1 genetic polymorphisms and cyclosporine pharmacokinetics after renal transplantation. Clin Pharmacol Ther 2004; 75: 422–433.
Haufroid V, Mourad M, Van Kerckhove V, Wawrzyniak J, De Meyer M, Eddour DC et al. The effect of CYP3A5 and MDR1 (ABCB1) polymorphisms on cyclosporine and tacrolimus dose requirements and trough blood levels in stable renal transplant patients. Pharmacogenetics 2004; 14: 147–154.
Yates CR, Zhang W, Song P, Li S, Gaber AO, Kotb M et al. The effect of CYP3A5 and MDR1 polymorphic expression on cyclosporine oral disposition in renal transplant patients. J Clin Pharmacol 2003; 43: 555–564.
Zhao Y, Song M, Guan D, Bi S, Meng J, Li Q et al. Genetic polymorphisms of CYP3A5 genes and concentration of the cyclosporine and tacrolimus. Transplant Proc 2005; 37: 178–181.
Chu XM, Hao HP, Wang GJ, Guo LQ, Min PQ . Influence of CYP3A5 genetic polymorphism on cyclosporine A metabolism and elimination in Chinese renal transplant recipients. Acta Pharmacol Sin 2006; 27: 1504–1508.
Chen B, Zhang W, Fang J, Jin Z, Li J, Yu Z et al. Influence of the MDR1 haplotype and CYP3A5 genotypes on cyclosporine blood level in Chinese renal transplant recipients. Xenobiotica 2009; 39: 931–938.
Singh R, Srivastava A, Kapoor R, K Sharma R, D Mittal R . Impact of CYP3A5 and CYP3A4 gene polymorphisms on dose requirement of calcineurin inhibitors, cyclosporine and tacrolimus, in renal allograft recipients of North India. Naunyn Schmiedebergs Arch Pharmacol 2009; 380: 169–177.
Loh PT, Lou HX, Zhao Y, Chin YM, Vathsala A . Significant impact of gene polymorphisms on tacrolimus but not cyclosporine dosing in Asian renal transplant recipients. Transplant Proc 2008; 40: 1690–1695.
Eng HS, Mohamed Z, Calne R, Lang CC, Mohd MA, Seet WT et al. The influence of CYP3A gene polymorphisms on cyclosporine dose requirement in renal allograft recipients. Kidney Int 2006; 69: 1858–1864.
Min DI, Ellingrod VL, Marsh S, McLeod H . CYP3A5 polymorphism and the ethnic differences in cyclosporine pharmacokinetics in healthy subjects. Ther Drug Monit 2004; 26: 524–528.
Utecht KN, Hiles JJ, Kolesar J . Effects of genetic polymorphisms on the pharmacokinetics of calcineurin inhibitors. Am J Health Syst Pharm 2006; 63: 2340–2348.
Falck P, Midtvedt K, Van Le TT, Storehagen L, Holdaas H, Hartmann A et al. A population pharmacokinetic model of ciclosporin applicable for assisting dose management of kidney transplant recipients. Clin Pharmacokinet 2009; 48: 615–623.
Acknowledgements
This work was supported by the Nanjing Health Bureau Foundation (Grant. no. ZKX08029).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Rights and permissions
About this article
Cite this article
Zhu, H., Yuan, S., Fang, Y. et al. The effect of CYP3A5 polymorphism on dose-adjusted cyclosporine concentration in renal transplant recipients: a meta-analysis. Pharmacogenomics J 11, 237–246 (2011). https://doi.org/10.1038/tpj.2010.26
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/tpj.2010.26
Keywords
This article is cited by
-
Comparison of genetic variation in drug ADME-related genes in Thais with Caucasian, African and Asian HapMap populations
Journal of Human Genetics (2016)